In The Press
- YaleFin Explores Venture Capital Investing in Healthcare InnovationThe following excerpt was taken from Yale Alumni—continue reading here. NEW YORK — Over 60 people recently gathered in New York City for a panel program spearheaded by YaleFin, an alumni shared interest group for those working in banking, finance, and the markets. The event focused on venture capital investing in healthcare innovation, while also… Read more: YaleFin Explores Venture Capital Investing in Healthcare Innovation
- Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk PharmaceuticalsThe following excerpt was taken from PR Newswire– continue reading here. NEW YORK, Dec. 10, 2025 /PRNewswire/ — Formation Bio and Lynk Pharmaceuticals today announced Formation Bio’s acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant highly selective TYK2 inhibitor. The asset will be developed within Formation’s newly formed subsidiary Bleecker Bio. LNK01006… Read more: Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk Pharmaceuticals